Peter Y. Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Peter Y. Zhao has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Abigail T. Fahim
Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan
1 shared publication- Alan Lee Robin
Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD; Department of Ophthalmology, University of Michigan, Ann Arbor, Michigan
1 shared publication - Anna Marmalidou
Schepens Eye Research Institute of Massachusetts Eye and Ear, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts; Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts
1 shared publication Benjamin K. Young
Casey Eye Institute, Oregon Health and Sciences University, Portland, Oregon
1 shared publication- Brian C. Stagg
Moran Eye Center, University of Utah, Salt Lake City, Utah, USA
1 shared publication - Christine A. Curcio
Department of Ophthalmology and Visual Sciences, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
1 shared publication
Latest Publications
- Open Access
- 27 October 2026
- Published by Elsevier in Ophthalmology Science
Reflectivity of the Hyperautofluorescent Ring in Retinitis Pigmentosa on High-resolution Optical Coherence Tomography
- 27 October 2026
- Published by Elsevier in Ophthalmology Science
Open AccessReflectivity of the Hyperautofluorescent Ring in Retinitis Pigmentosa on High-resolution Optical Coherence Tomography
- 9 October 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 8 (1) , e1-E1
Re: Momenaei et al.: Appropriateness and readability of ChatGPT-4–generated responses for surgical treatment of retinal diseases (Ophthalmol Retina. 2023:7:862-868)
- 9 October 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 8 (1) , e1-E1
Re: Momenaei et al.: Appropriateness and readability of ChatGPT-4–generated responses for surgical treatment of retinal diseases (Ophthalmol Retina. 2023:7:862-868)
- 26 May 2022
- Published by Elsevier in Ophthalmology Retina
- Vol. 6 (11) , 1098-1104
Automated Segmentation of Autofluorescence Lesions in Stargardt Disease
- 26 May 2022
- Published by Elsevier in Ophthalmology Retina
- Vol. 6 (11) , 1098-1104
Automated Segmentation of Autofluorescence Lesions in Stargardt Disease
- Open Access
- 1 November 2018
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 136 (11) , 1271-1279
A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery
Importance Medical and surgical interventions for glaucoma are effective only if they are affordable to patients. Little is known about how affordable glaucoma interventions are in developing and developed countries. Objective To compare the prices of topical glaucoma medications, laser trabeculoplasty, and trabeculectomy relative with median annual household income (MA-HHI) for countries worldwide. Design, Setting and Participants Cross-sectional observational study. For each country, we obtained prices for glaucoma medications, laser trabeculoplasty, and trabeculectomy using government pricing data, drug databases, physician fee schedules, academic publications, and communications with local ophthalmologists. Prices were adjusted for purchasing power parity and inflation to 2016 US dollars, and annual therapy prices were examined relative to the MA-HHI. Interventions costing less than 2.5% of the MA-HHI were considered affordable. Main Outcomes and Measures Daily cost for topical glaucoma medications, cost of annual therapy with glaucoma medications, laser trabeculoplasty, and trabeculectomy relative to MA-HHI in each country. Results Data were obtained from 38 countries, including 17 developed countries and 21 developing countries, as classified by the World Economic Outlook. We observed considerable variability in intervention prices compared with MA-HHI across the countries and across interventions, ranging from 0.1% to 5% of MA-HHI for timolol, 0.1% to 27% for latanoprost, 0.2% to 17% for laser trabeculoplasty, and 0.3% to 42% for trabeculectomy. Timolol was the most affordable medication in all countries studied and was 2.5% or more of MA-HHI in only 2 countries (5%). The annual cost of latanoprost was 2.5% or more of MA-HHI in 15 countries (41%) (15 developing countries [75%] and no developed countries). The cost of laser trabeculoplasty was 2.5% or more of the MA-HHI in 15 countries (44%) (11 developing countries [65%] and 4 developed countries [24%]). The cost of trabeculectomy was 2.5% or more of the MA-HHI in 28 countries (78%) (18 developing countries [95%] and 10 developed countries [59%]). In 18 countries (53%), laser trabeculoplasty cost less than a 3-year latanoprost supply. Conclusions and Relevance For many patients worldwide, the costs of medical, laser, and incisional surgical interventions were 2.5% or more of the MA-HHI. Successfully reducing global blindness from glaucoma requires addressing multiple contributing factors, including making glaucoma interventions more affordable.
- 1 November 2018
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 136 (11) , 1271-1279
Open AccessA Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery
Importance Medical and surgical interventions for glaucoma are effective only if they are affordable to patients. Little is known about how affordable glaucoma interventions are in developing and developed countries. Objective To compare the prices of topical glaucoma medications, laser trabeculoplasty, and trabeculectomy relative with median annual household income (MA-HHI) for countries worldwide. Design, Setting and Participants Cross-sectional observational study. For each country, we obtained prices for glaucoma medications, laser trabeculoplasty, and trabeculectomy using government pricing data, drug databases, physician fee schedules, academic publications, and communications with local ophthalmologists. Prices were adjusted for purchasing power parity and inflation to 2016 US dollars, and annual therapy prices were examined relative to the MA-HHI. Interventions costing less than 2.5% of the MA-HHI were considered affordable. Main Outcomes and Measures Daily cost for topical glaucoma medications, cost of annual therapy with glaucoma medications, laser trabeculoplasty, and trabeculectomy relative to MA-HHI in each country. Results Data were obtained from 38 countries, including 17 developed countries and 21 developing countries, as classified by the World Economic Outlook. We observed considerable variability in intervention prices compared with MA-HHI across the countries and across interventions, ranging from 0.1% to 5% of MA-HHI for timolol, 0.1% to 27% for latanoprost, 0.2% to 17% for laser trabeculoplasty, and 0.3% to 42% for trabeculectomy. Timolol was the most affordable medication in all countries studied and was 2.5% or more of MA-HHI in only 2 countries (5%). The annual cost of latanoprost was 2.5% or more of MA-HHI in 15 countries (41%) (15 developing countries [75%] and no developed countries). The cost of laser trabeculoplasty was 2.5% or more of the MA-HHI in 15 countries (44%) (11 developing countries [65%] and 4 developed countries [24%]). The cost of trabeculectomy was 2.5% or more of the MA-HHI in 28 countries (78%) (18 developing countries [95%] and 10 developed countries [59%]). In 18 countries (53%), laser trabeculoplasty cost less than a 3-year latanoprost supply. Conclusions and Relevance For many patients worldwide, the costs of medical, laser, and incisional surgical interventions were 2.5% or more of the MA-HHI. Successfully reducing global blindness from glaucoma requires addressing multiple contributing factors, including making glaucoma interventions more affordable.